Novartis AG ADR (NVS)vsOrganogenesis Holdings Inc (ORGO)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
ORGO
Organogenesis Holdings Inc
$1.49
-2.61%
HEALTHCARE · Cap: $220.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 12293% more annual revenue ($56.69B vs $457.45M). NVS leads profitability with a 22.5% profit margin vs -18.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
ORGO
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for ORGO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Earnings expanding 555.0% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.7% — below average capital efficiency
Weak financial health signals
Revenue declined 56.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : ORGO
The strongest argument for ORGO centers on Price/Book, EPS Growth, Altman Z-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while ORGO is a turnaround play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.29 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 41/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?